Tuberculosis (TB) Diagnostics Market to Reach US$ 4.15 Billion by 2031, Driven by Molecular Testing Adoption and Global TB Elimination Efforts | QY Research

Market Summary -

The global Tuberculosis (TB) Diagnostics Market is poised for steady growth as public health systems intensify efforts to improve early detection, treatment initiation, and disease surveillance worldwide. According to the latest study titled "Tuberculosis (TB) Diagnostics Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031," the market was valued at US$ 3,070 million in 2024 and is projected to reach US$ 4,149 million by 2031, expanding at a CAGR of 4.5% during the forecast period from 2025 to 2031.

Tuberculosis is a contagious infectious disease caused by Mycobacterium tuberculosis (MTB), most commonly affecting the lungs but also capable of involving other organs. While many individuals carry latent TB without symptoms, approximately 10% progress to active disease, which can be fatal if untreated. Persistent global TB incidence-particularly in Asia-Pacific, Africa, and parts of Latin America-continues to make accurate and timely diagnostics a cornerstone of TB control strategies.

Get Full PDF Sample Copy of the Report: (Including Full TOC, Tables & Charts): https://qyresearch.in/request-sample/medical-care-tuberculosis-tb-diagnostics-market-share-and-ranking-overall-sales-and-demand-forecast-2025-2031

Market Drivers and Public Health Initiatives -

Growth in the TB diagnostics market is being propelled by the ongoing global burden of tuberculosis and renewed international commitment to achieving the WHO End TB Strategy goals. Governments, global health agencies, and donors are increasing funding for TB programs, accelerating the deployment of advanced diagnostic technologies.

Key growth drivers include the rapid adoption of molecular diagnostics, such as nucleic acid amplification tests, which enable faster and more accurate detection of TB and drug resistance. In parallel, AI-assisted digital X-ray screening and point-of-care diagnostic tools are expanding access to testing in decentralized and resource-limited settings. Integration of TB screening into broader healthcare initiatives-such as universal health coverage, respiratory disease programs, and HIV care-has further increased testing volumes.

Targeted screening of high-risk populations, including people living with HIV, healthcare workers, migrants, and incarcerated individuals, is also driving demand for rapid, same-day diagnostic solutions that can guide immediate treatment decisions and reduce transmission.

Competitive Landscape -

The global TB diagnostics market is moderately consolidated, with multinational life sciences and diagnostics companies playing a dominant role. Key companies profiled in the report include Danaher, Roche, Thermo Fisher Scientific, BD, Abbott, Qiagen, and bioMérieux. Collectively, the top five manufacturers account for approximately 33% of global market share, reflecting strong technological leadership and global distribution capabilities.

Danaher
Roche
Thermo Fisher Scientific
BD
Abbott
Hologic
Qiagen
BioMerieux
Hain Lifescience
Oxford Immunotec

Regional Insights -

The Asia-Pacific region represents the largest TB diagnostics market, accounting for over 40% of global revenue, driven by high disease prevalence, large-scale national TB programs, and increasing access to molecular testing in countries such as India, China, and Southeast Asia. The Americas and Europe together account for around 40% of the market, supported by advanced laboratory infrastructure, strong regulatory frameworks, and continued innovation in diagnostic platforms.

✔ North America (U.S., Canada, China)
✔ Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
✔ Asia-Pacific (Japan, South Korea, China Taiwan, Southeast Asia, India)
✔ Middle East, Africa, Latin America (Brazil, Mexico, Turkey, Israel, GCC Countries)

Market Challenges and Barriers -

Despite technological progress, significant challenges continue to constrain market expansion. Limited access to advanced diagnostics in low- and middle-income countries remains a critical issue, as many regions lack the laboratory infrastructure and trained personnel needed to support widespread deployment. The high cost of molecular and imaging-based technologies, along with ongoing expenses for consumables, maintenance, and training, can limit adoption in resource-constrained settings.

Logistical and regulatory hurdles-particularly in rural and remote areas-also slow implementation. In addition, inconsistent diagnostic algorithms and reimbursement policies across countries, coupled with fragile supply chains, hinder uniform adoption of guideline-recommended testing and reduce the overall impact of TB control efforts.

Scope of the Report -

This report provides a comprehensive analysis of the global tuberculosis diagnostics market, focusing on total sales revenue, company market share and ranking, and competitive dynamics. It delivers detailed insights by region and country, by type (culture-based diagnostics, sputum smear microscopy, rapid molecular diagnostics, and others), and by application (diagnostic laboratories and hospitals). Based on 2024 as the base year, with historical data from 2020 to 2024 and forecasts through 2031, the study combines quantitative and qualitative analysis to help stakeholders assess market positioning, identify growth opportunities, and make informed strategic decisions in the evolving TB diagnostics landscape.

Market Segmentation and Regional -

By Type

Culture-Based Diagnostics
Sputum Smear Microscopy
Rapid Molecular Diagnostics
Others

By Application

Diagnostic Laboratories
Hospitals

The report provides valuable insights into the key segments of the global Tuberculosis (TB) Diagnostics market, with a strong focus on CAGR, market size, market share, and future growth potential. The market is comprehensively segmented by product type, application, and region, with each segment thoroughly analyzed to identify growth prospects, demand patterns, and emerging trends. This detailed segmental analysis plays a crucial role in uncovering high-growth and high-return opportunities across the market. By offering precise data on product- and application-level demand, the report enables businesses to prioritize profitable segments and develop targeted strategies within the global Tuberculosis (TB) Diagnostics market.

Reasons to Procure this Report: -

►The research would help top administration/policymakers/professionals/product advancements/sales managers and stakeholders in this market in the following ways.

►The report provides Tuberculosis (TB) Diagnostics market revenues at the worldwide, regional, and country-level with a complete analysis to 2028 permitting companies to analyze their market share and analyze projections, and find new markets to aim.

►The research includes the Tuberculosis (TB) Diagnostics market split by different types, applications, technologies, and end-uses. This segmentation helps leaders plan their products and finances based on the upcoming development rates of each segment.

►Tuberculosis (TB) Diagnostics market analysis benefits investors by knowing the scope and position of the market giving them information on key drivers, challenges, restraints, and expansion chances of the market and moderate threats.

►This report would help to understand competition better with a detailed analysis and key strategies of their competitors and plan their position in the business.

►The study helps evaluate Tuberculosis (TB) Diagnostics business predictions by region, key countries, and top companies' information to channel their investments.

Key questions answered in the report include:

►This Tuberculosis (TB) Diagnostics report gives all the information about the industry analysis, revenue, and overview, of this market.

►What will be the rate of increase in Tuberculosis (TB) Diagnostics market size and growth rate by the end of the forecast period?

►What are the major global Tuberculosis (TB) Diagnostics market trends influencing the development of the market?

►What are the vital results of SWOT analysis of the major players operating in the Tuberculosis (TB) Diagnostics market?

►What are the potential growth opportunities and threats faced by Major competitors in the Tuberculosis (TB) Diagnostics market?

►What are the market opportunities and threats faced by vendors in the Global Tuberculosis (TB) Diagnostics market?

Request for Pre-Order / Enquiry Link: https://qyresearch.in/pre-order-inquiry/medical-care-tuberculosis-tb-diagnostics-market-share-and-ranking-overall-sales-and-demand-forecast-2025-2031

Table of Contents - Major Key Points:

1 Market Overview
1.1 Tuberculosis (TB) Diagnostics Product Introduction
1.2 Global Tuberculosis (TB) Diagnostics Market Size Forecast (2020-2031)
1.3 Tuberculosis (TB) Diagnostics Market Trends & Drivers
1.3.1 Tuberculosis (TB) Diagnostics Industry Trends
1.3.2 Tuberculosis (TB) Diagnostics Market Drivers & Opportunity
1.3.3 Tuberculosis (TB) Diagnostics Market Challenges
1.3.4 Tuberculosis (TB) Diagnostics Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Tuberculosis (TB) Diagnostics Players Revenue Ranking (2024)
2.2 Global Tuberculosis (TB) Diagnostics Revenue by Company (2020-2025)
2.3 Key Companies Tuberculosis (TB) Diagnostics Manufacturing Base Distribution and Headquarters
2.4 Key Companies Tuberculosis (TB) Diagnostics Product Offered
2.5 Key Companies Time to Begin Mass Production of Tuberculosis (TB) Diagnostics
2.6 Tuberculosis (TB) Diagnostics Market Competitive Analysis
2.6.1 Tuberculosis (TB) Diagnostics Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Tuberculosis (TB) Diagnostics Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tuberculosis (TB) Diagnostics as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Culture-Based Diagnostics
3.1.2 Sputum Smear Microscopy
3.1.3 Rapid Molecular Diagnostics
3.1.4 Others
3.2 Global Tuberculosis (TB) Diagnostics Sales Value by Type
3.2.1 Global Tuberculosis (TB) Diagnostics Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Tuberculosis (TB) Diagnostics Sales Value, by Type (2020-2031)
3.2.3 Global Tuberculosis (TB) Diagnostics Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Diagnostic Laboratories
4.1.2 Hospitals
4.2 Global Tuberculosis (TB) Diagnostics Sales Value by Application
4.2.1 Global Tuberculosis (TB) Diagnostics Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Tuberculosis (TB) Diagnostics Sales Value, by Application (2020-2031)
4.2.3 Global Tuberculosis (TB) Diagnostics Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
5.1 Global Tuberculosis (TB) Diagnostics Sales Value by Region
5.1.1 Global Tuberculosis (TB) Diagnostics Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Tuberculosis (TB) Diagnostics Sales Value by Region (2020-2025)
5.1.3 Global Tuberculosis (TB) Diagnostics Sales Value by Region (2026-2031)
5.1.4 Global Tuberculosis (TB) Diagnostics Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
5.2.2 North America Tuberculosis (TB) Diagnostics Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
5.3.2 Europe Tuberculosis (TB) Diagnostics Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
5.4.2 Asia Pacific Tuberculosis (TB) Diagnostics Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
5.5.2 South America Tuberculosis (TB) Diagnostics Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
5.6.2 Middle East & Africa Tuberculosis (TB) Diagnostics Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Tuberculosis (TB) Diagnostics Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
6.3 United States
6.3.1 United States Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
6.3.2 United States Tuberculosis (TB) Diagnostics Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Tuberculosis (TB) Diagnostics Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
6.4.2 Europe Tuberculosis (TB) Diagnostics Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Tuberculosis (TB) Diagnostics Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
6.5.2 China Tuberculosis (TB) Diagnostics Sales Value by Type (%), 2024 VS 2031
6.5.3 China Tuberculosis (TB) Diagnostics Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
6.6.2 Japan Tuberculosis (TB) Diagnostics Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Tuberculosis (TB) Diagnostics Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
6.7.2 South Korea Tuberculosis (TB) Diagnostics Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Tuberculosis (TB) Diagnostics Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
6.8.2 Southeast Asia Tuberculosis (TB) Diagnostics Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Tuberculosis (TB) Diagnostics Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
6.9.2 India Tuberculosis (TB) Diagnostics Sales Value by Type (%), 2024 VS 2031
6.9.3 India Tuberculosis (TB) Diagnostics Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Danaher
7.1.1 Danaher Profile
7.1.2 Danaher Main Business
7.1.3 Danaher Tuberculosis (TB) Diagnostics Products, Services and Solutions
7.1.4 Danaher Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
7.1.5 Danaher Recent Developments
7.2 Roche
7.2.1 Roche Profile
7.2.2 Roche Main Business
7.2.3 Roche Tuberculosis (TB) Diagnostics Products, Services and Solutions
7.2.4 Roche Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
7.2.5 Roche Recent Developments
7.3 Thermo Fisher Scientific
7.3.1 Thermo Fisher Scientific Profile
7.3.2 Thermo Fisher Scientific Main Business
7.3.3 Thermo Fisher Scientific Tuberculosis (TB) Diagnostics Products, Services and Solutions
7.3.4 Thermo Fisher Scientific Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
7.3.5 Thermo Fisher Scientific Recent Developments
7.4 BD
7.4.1 BD Profile
7.4.2 BD Main Business
7.4.3 BD Tuberculosis (TB) Diagnostics Products, Services and Solutions
7.4.4 BD Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
7.4.5 BD Recent Developments
7.5 Abbott
7.5.1 Abbott Profile
7.5.2 Abbott Main Business
7.5.3 Abbott Tuberculosis (TB) Diagnostics Products, Services and Solutions
7.5.4 Abbott Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
7.5.5 Abbott Recent Developments
7.6 Hologic
7.6.1 Hologic Profile
7.6.2 Hologic Main Business
7.6.3 Hologic Tuberculosis (TB) Diagnostics Products, Services and Solutions
7.6.4 Hologic Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
7.6.5 Hologic Recent Developments
7.7 Qiagen
7.7.1 Qiagen Profile
7.7.2 Qiagen Main Business
7.7.3 Qiagen Tuberculosis (TB) Diagnostics Products, Services and Solutions
7.7.4 Qiagen Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
7.7.5 Qiagen Recent Developments
7.8 BioMerieux
7.8.1 BioMerieux Profile
7.8.2 BioMerieux Main Business
7.8.3 BioMerieux Tuberculosis (TB) Diagnostics Products, Services and Solutions
7.8.4 BioMerieux Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
7.8.5 BioMerieux Recent Developments
7.9 Hain Lifescience
7.9.1 Hain Lifescience Profile
7.9.2 Hain Lifescience Main Business
7.9.3 Hain Lifescience Tuberculosis (TB) Diagnostics Products, Services and Solutions
7.9.4 Hain Lifescience Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
7.9.5 Hain Lifescience Recent Developments
7.10 Oxford Immunotec
7.10.1 Oxford Immunotec Profile
7.10.2 Oxford Immunotec Main Business
7.10.3 Oxford Immunotec Tuberculosis (TB) Diagnostics Products, Services and Solutions
7.10.4 Oxford Immunotec Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
7.10.5 Oxford Immunotec Recent Developments
8 Industry Chain Analysis
8.1 Tuberculosis (TB) Diagnostics Industrial Chain
8.2 Tuberculosis (TB) Diagnostics Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Tuberculosis (TB) Diagnostics Sales Model
8.5.2 Sales Channel
8.5.3 Tuberculosis (TB) Diagnostics Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

About Us:

QYResearch established as a research firm in 2007 and have since grown into a trusted brand amongst many industries. Over the years, we have consistently worked toward delivering high-quality customized solutions for wide range of clients ranging from ICT to healthcare industries. With over 50,000 satisfied clients, spread over 80 countries, we have sincerely strived to deliver the best analytics through exhaustive research methodologies.

Contact Us:

Arshad Shaha | Marketing Executive

QY Research, INC.
315 Work Avenue, Raheja Woods,
Survey No. 222/1, Plot No. 25, 6th Floor,
Kayani Nagar, Yervada, Pune 411006, Maharashtra
Tel: +91-8669986909
Emails - arshad@qyrindia.com
Web - https://www.qyresearch.in

This release was published on openPR.